Exploratory study of CL2020 in ST-elevation acute myocardial infarctio
Phase 1
Completed
- Conditions
- ST-elevation myocardial infarction
- Registration Number
- JPRN-jRCT1080223778
- Lead Sponsor
- ife Science Institute. Inc.
- Brief Summary
When CL2020 was intravenously administered once to the patients with ST-elevation myocardial infarction (STEMI), no major concern on safety was reported during 52-week observation period. The results of efficacy endpoints show the efficacy of CL2020 on cardiac function of the patients with STEMI.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 3
Inclusion Criteria
Patients with ST-elevation acute myocardial infarction with successful reperfusion by PCI
etc.
Exclusion Criteria
-Previous myocardial infarction
-Cardiogenic shock
-Cerebral vascular disease (cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, etc.) or transient ischemic attach within 3 months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety<br>Safety of CL2020
- Secondary Outcome Measures
Name Time Method efficacy<br>Efficacy of CL2020 on cardiac function, etc.